RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

More on Xenoport (XNPT):



XNPT's Profitability a Bit Distant

Oct 02, 2007 (Zacks Investment Research via COMTEX) -- A Hold recommendation has recently been issued to pharmaceutical company XenoPort, Inc. (XNPT) by Zacks senior bio-medical analyst Jason Napodano, CFA.nbsp; Here's what his latest update had to say about it:'XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of central nervous system (CNS) disorders and gastroesophageal reflux disease (GERD). The lead candidate is XP-13512, a Transported Prodrug of gabapentin. XenoPort is partnered with GlaxoSmithKline (GSK), for development and commercialization in the U.S. and select countries outside the U.S. 'The drug is in late-stage trials for the treatment of Restless Leg Syndrome (RLS). So far the data has been highly encouraging. XP-13512 could launch in 2009. We rate the shares Hold with a $52 target. 'We consider XP-13512 to be potential blockbuster opportunity with a full label to include both RLS and neuropathic pain. As for now we are holding off on modeling sales in neuropathic pain until we see more data. We think the company can earn $2.30 in 2011 and potentially over $3.50 in EPS in 2012. 'We feel that $52 a market capitalization of $1.35 billion is a fair value for the current fundamentals. Positive data on XP-13512 from the remaining trials or a positive update on XP-19986 could send the shares higher.'Read the full analyst report on XNPT. Read the full analyst report on GSK.



Interesting company with a nice pipeline and good partnerships, but nothing approved and a market cap of $1.2 billion.


Bladerunner